Thomas Jefferson University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Thomas Jefferson University sits in the top decile of US sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count).
Thomas Jefferson University: 292 sponsored US clinical trials, 54 recruiting.
Thomas Jefferson University sponsors 292 registered US clinical trials on ClinicalTrials.gov, 54 of them currently recruiting, and 182 completed. 46 of these trials are in Phase 3-4 (later-stage) and 73 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malignant Solid Neoplasm, with 4 trials.
Top-decile sponsor footprint
Thomas Jefferson University ranks in the top decile of sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
182 of 210 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
292 total, page 3 of 6
A Chatbot-Powered G8 Screening Intervention to Facilitate Referrals to a Comprehensive Geriatric Assessment Among Older Adults With Cancer
NCT05535140
Telehealth-enabled Integrated Palliative Care for People With Dementia
NCT05524181
Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?
NCT05021263
Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
NCT05536037
Gynecological Sentinel Lymph Nodes CEUS
NCT05105087
Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast Cancer
NCT06206239
Pharmacokinetics of Progesterone in Pregnancy-2
NCT04753957
Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
NCT04283656
Child Healthcare at MATER - Pediatric Study
NCT05488379
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
NCT05328167
Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass
NCT05357885
Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: a Randomized Clinical Trial
NCT04259047
Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection
NCT04765449
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
NCT04177498
Measuring the Impact of MANNA s Medically Tailored Meal Program in Patients With a Non-terminal Cancer Diagnosis
NCT05118802
Closure of Mucosal and Submucosal Defects in the Gastrointestinal Tract Using the Novel X-Tack Endoscopic Suturing Device
NCT04925271
Improving Lung Cancer Screening Adherence by Overcoming Barriers for Vulnerable Populations
NCT04969341
Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment
NCT04788264
Ropivacaine Pharmacokinetics in ESP Blocks
NCT04807504
Cannabis Use Patterns Among Cancer Patients
NCT05132842
Linguistically-Tailored Mobile Intervention for the Improvement of Follow Up for Abnormal Pap Test Results
NCT04821297
Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues
NCT04822688
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
NCT04720417
Antenatal Platelet Response on Aspirin: a Pharmacokinetic Study Through Pregnancy
NCT04645004
Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
NCT04721886
COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes
NCT04659759
Rotational Thromboelastometry (ROTEM) TRUE-NATEM Reference Value Validation in Liver Transplantation
NCT04282889
Postplacental LNG-IUD Ultrasound Use Study
NCT04474548
Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial
NCT04294069
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
NCT04447703
Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)
NCT04295850
Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use
NCT04694846
Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions
NCT04492072
DexCom Hospital Study-CGM Directed Insulin Delivery
NCT05504785
Diagnosing Compartment Syndrome With SHAPE vs Elastography
NCT05247541
Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings
NCT03929783
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia
NCT04694820
Development of a Tracheal Sound Sensor
NCT05506267
Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study
NCT04449679
Convalescent Plasma for the Treatment of COVID-19
NCT04389710
COVID-19 Plasma Collection
NCT04344015
Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial
NCT04716920
A Trial to Evaluate Medically Tailored Meals With Patients With Heart Failure
NCT04289181
Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy
NCT04191928
Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment
NCT04788758
Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer
NCT04666428
Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes
NCT04264572
The Peer Genetic Study
NCT05011799
Blood Sample Collection for Experimental Blood Test to Track Liver Cancer
NCT04720430
Development of the Oncology Opportunity Cost Assessment Tool
NCT04694911
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 34 |
| Phase 3 | 19 |
| Phase 4 | 27 |
What is open in the Thomas Jefferson University pipeline
54 recruiting of 292 indexed (18% open); 182 completed (62%).
Phase mix: 46 late (III/IV) vs 73 early (I/II) (early-phase heavy).
Top condition: Malignant Solid Neoplasm (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Thomas Jefferson University: open-pipeline peers nationwide
Peers matched on 292 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Thomas Jefferson University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 292 trials (± recruiting share)
- University of Michigan Rogel Cancer Center · 292 trials · 15% recruiting
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
- Eisai · 287 trials · 2% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Florida Atlantic University · 19% recruiting · 27 trials
- Institut de Recherches Internationales Servier · 19% recruiting · 27 trials
- Natera · 19% recruiting · 27 trials
- Nemours Children's Clinic · 19% recruiting · 108 trials
Related
What to do with this Thomas Jefferson University page
292 registered trials is a research-attention snapshot, not an endorsement of Thomas Jefferson University or any single study.
- 54 of Thomas Jefferson University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Malignant Solid Neoplasm is the condition Thomas Jefferson University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malignant Solid Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Thomas Jefferson University pipeline card: 292 registered trials from official public datasets.Report a data error.